



MORBIDITY AND MORTALITY WEEKLY REPORT

- 1017 Impact of the Sequential IPV/OPV Schedule on Vaccination Coverage Levels — United States, 1997
- 1019 Fatal Car Trunk Entrapment Involving Children — United States, 1987–1998
- 1022 Forecasted State-Specific Estimates of Self-Reported Asthma Prevalence — United States, 1998
- **1025** Abortion Surveillance: Preliminary Analysis United States, 1996

Impact of the Sequential IPV/OPV Schedule on Vaccination Coverage Levels — United States, 1997

In January 1997, the Advisory Committee on Immunization Practices (ACIP) recommended adoption of a sequential inactivated poliovirus vaccine (IPV)—oral poliovirus vaccine (OPV) vaccination schedule (1). The schedule of injections of IPV at 2 months and 4 months of age, followed by OPV at 12–18 months and again at 4–6 years was intended to minimize the risk for vaccine-associated paralytic poliomyelitis (VAPP) while maintaining population immunity to the potential introduction of wild-type poliovirus. To determine whether this change may result in reduced or delayed vaccination coverage because parents or physicians might be reluctant to administer multiple injections at a single visit (2), CDC investigated the impact of the change to a sequential IPV-OPV vaccination schedule at two large West coast health maintenance organizations (HMOs). This report summarizes the results of the investigation and indicates that changing to an initial two doses of IPV was not associated with decreases in vaccination coverage levels of routinely recommended vaccinations.

This study focused on children enrolled at Group Health Cooperative of Puget Sound (GHC), a Seattle-based HMO with approximately 530,000 members, and Kaiser Permanente of Northern California (KPNC), an Oakland-based HMO with approximately 2.8 million members. Both sites have automated vaccination tracking systems (3) that allow for assessment of vaccination coverage by region, clinic, and individual patient. Beginning in April 1997, GHC adopted the ACIP guidelines for the sequential IPV schedule as an option for physicians and families. Within KPNC, each of its 17 medical centers made a local decision about whether and when to adopt the IPV schedule. Children in the study were born during October 1, 1996-June 30, 1997; resided in King, Pierce, Thurston, and Kitsap counties, Washington, and all counties of the KPNC region; had been continuously enrolled during the first 12 months of life; and had received at least one polio vaccination (N=1745 GHC and 15,707 KPNC enrollees). Up-to-date status, defined as receipt of two polio vaccinations, three diphtheria and tetanus toxoids and pertussis/acellular pertussis (DTP/DTaP) vaccinations, and two Haemophilus influenzae type b and two hepatitis B vaccinations administered after age 3 weeks, was measured at age 12 months.

The percentage of GHC children who received their first polio vaccine as IPV increased from 18% during the fourth quarter of 1996, to 19% in the first, 34% in the second, and 82% in the third quarter of 1997. Among GHC clinics that had at least 20

IPV/OPV Vaccination Coverage — Continued

children in the evaluation, the percentage of children who received IPV during the third quarter of 1997 ranged from 81% to 98%. In comparison, at KPNC, the percentages by quarter were 10%, 15%, 24%, and 36%, respectively; among KPNC clinics that had at least 20 children in the evaluation, the percentage of children who received IPV during the fourth quarter ranged from 6% to 98%. Among GHC children who received IPV as their first polio vaccination, vaccination up-to-date status by age 12 months for routinely recommended vaccines was 82%, 83%, and 82% in the first three quarters following implementation, and among those receiving OPV, vaccination up-to-date status was 82%, 81%, and 79%, respectively. At KPNC, the quarterly up-to-date percentages were 90%, 89%, and 91% for children receiving IPV, and 92%, 90%, and 91% for children receiving OPV.

After adjusting for sex, trends over time, Medicaid status, and primary clinic, GHC children receiving IPV as their first polio vaccination were as likely to be up-to-date at age 12 months as children receiving OPV (risk ratio [RR]=1.1; 95% confidence interval [CI]=1.0–1.3). KPNC children receiving IPV as their first polio vaccination also were as likely as those receiving OPV to be up-to-date (RR=1.0; 95% CI=0.9–1.0). At GHC, children enrolled in Medicaid had lower coverage levels at age 12 months (71% up-to-date among Medicaid enrollees compared with 83% among nonenrollees); KPNC Medicaid enrollees and non-Medicaid enrollees had similar up-to-date status (90% compared with 91%, respectively). Among GHC Medicaid enrollees, vaccination with IPV was not significantly associated with a decreased up-to-date status (68% at age 12 months among IPV recipients compared with 73% at age 12 months among OPV recipients). At KPNC, Medicaid enrollees receiving IPV were as likely to be up-to-date as those receiving OPV (91% compared with 90%, respectively).

Reported by: RL Davis, LK Mell, A Zavitkovsky, RS Thompson, Immunization Studies Program, Center for Health Studies, Group Health Cooperative, Seattle, Washington. TA Lieu, Div of Research, AM Capra, C Quesenberry, SB Black, HR Shinefield, Kaiser Permanente of Northern California, Oakland, California. Child Vaccine Preventable Diseases Br, Epidemiology and Surveillance Div and Health Svcs Research and Evaluation Br, Immunization Svcs Div, National Immunization Program, CDC.

Editorial Note: The findings in this report indicate that use of IPV for the initial polio vaccine doses in these two West coast HMOs was not associated with decreases in vaccination coverage levels. These findings are consistent with evaluations conducted in other settings, including clinics serving children from low-income families (4–6).

An important ancillary finding from the study was that the sequential polio vaccination schedule was implemented to a much greater degree in the HMO that used a more centralized decision making process than in the HMO that relied on local decision making (82% compared with 36%, respectively, for the percentage of children who received IPV for their initial polio vaccination). In the United States, use of IPV increased from 6% of all polio vaccine doses distributed in 1996 to 29% in 1997 (CDC, unpublished data, 1998).

Despite the increased use of IPV, four cases of VAPP have occurred in the United States since January 1997. All cases were associated with receipt of the first or second dose of OPV vaccine in an all OPV schedule; three cases were in OPV recipients, and one case was in an adult contact of an OPV recipient.

To further reduce the incidence of VAPP by decreasing reliance on OPV for the initial doses of poliovirus vaccine, in October 1998, ACIP changed the routine childhood polio vaccination schedule. Use of OPV is no longer recommended for the first two doses

IPV/OPV Vaccination Coverage — Continued

except in special circumstances (e.g., a child whose parents do not accept the recommended number of injections or who will be traveling to areas with endemic polio). OPV remains the vaccine of choice for mass vaccination campaigns to control outbreaks associated with wild poliovirus.

References

- CDC. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46 (no. RR-3).
- 2. Melman ST, Chawla J, Kaplan JM, Anhar RD. Multiple immunizations: ouch! Arch Fam Med 1994;3:615–7.
- 3. Davis RL, Black S, Vadheim C, et al. Immunization tracking systems: experience of the CDC Vaccine Safety Datalink sites. HMO Practice 1997;11:13–7.
- 4. Kolasa M, Desai S, Bisgard K, Prevots R. Is the new poliovirus recommendation acceptable to parents? Abstracts of the 1998 Pediatric Academic Societies' Annual Meeting. New Orleans, Louisiana, June 12–14, 1997.
- 5. Melman ST, Ehrlich ES, Klugman D, Nguyen TT, Anbar RD. Parental compliance with initiation of the sequential schedule for infant polio immunization. 1998 Pediatric Academic Societies' Annual Meeting, May 1–5, 1998, New Orleans, Louisiana. Abstract no. 104.
- 6. Stevenson JM, Chen W, Brown P, Maley M. Implementation and impact of the ACIP recommended sequential schedule for IPV/OPV. 1998 Pediatric Academic Societies' Annual Meeting, May 1–5, 1998, New Orleans, LA. Abstract no. 363.

Fatal Car Trunk Entrapment Involving Children — United States, 1987–1998

During July–August 1998, at least 11 U.S. children died in three separate incidents of car trunk entrapment. This report summarizes these three incidents, describes characteristics of car trunk entrapment incidents involving children since 1987, and reviews measures to prevent children from becoming trapped in car trunks. The findings indicate that at least nine incidents of fatal car trunk entrapment involving children occurred during 1987–1998, that all incidents occurred in hot weather and involved children aged ≤6 years, and that these deaths were preventable.

Case Reports

Incident 1. On July 13, 1998, at approximately 6 p.m., four children aged 2–5 years were discovered inside the closed trunk of a car in Gallup, New Mexico. The children had climbed into the car's open trunk and had not been seen for 1 hour before a search began. They were found approximately 1 hour after the search began. The outside ambient temperature that afternoon was 90 F (32.2 C). The children were rushed to a local emergency department, where three were pronounced dead. The remaining child, a 5-year-old girl, was transported to a tertiary-care hospital, where her rectal temperature was recorded at 108 F (42.2 C); she died on July 14. No carbon monoxide was detected in blood samples of the children. The autopsy report cited hyperthermia and asphyxia as the causes of death.

Incident 2. On August 2, 1998, at approximately 1 p.m., two brothers aged 2 and 5 years from Greene County, Pennsylvania, were found dead in the trunk of their parents' car in front of their house. The boys had found the car keys, opened the trunk, and climbed inside. They were missing for several hours during the morning and early

Fatal Car Trunk Entrapment — Continued

afternoon. The outside ambient temperature that afternoon was approximately 85 F (29.5 C). The autopsy report cited hyperthermia and asphyxia as the causes of death.

Incident 3. On August 8, 1998, at 4:15 p.m., five girls in West Valley City, Utah, aged 2–6 years, were found dead inside the trunk of a car owned by one of the children's parents. The car had been parked at one of the children's residence. The outside ambient temperature was 100 F (37.8 C). The vehicle's trunk-release lever was adjacent to the driver's seat, and at least one of the two 6-year-old girls reportedly knew how to operate the release lever. The children had not been seen for approximately 20 minutes before a search began and were found approximately 1½ hours after the search began. Liver temperatures taken at the death scene 1½–2 hours after the children were found ranged from 99 F to 117 F (37.2 C to 47.2 C). The autopsy report cited the cause of death as hyperthermia.

Surveillance for Fatalities Associated with Trunk Entrapments, 1987–1998

The LEXIS-NEXIS database (1) was used to search newspapers, magazines, wire services, and broadcast transcripts for additional deaths associated with car trunk entrapment. During 1987–1998, nine incidents were identified of fatal car trunk entrapment involving children, including the three incidents described in this report. Medical examiner/coroner (ME/C) offices were contacted for information about death investigations and autopsy findings. ME/C offices provided written and verbal cause-of-death information for seven of the incidents, and for two incidents, information was obtained from media sources, who cited coroner's reports for cause-of-death information.

A total of 19 children aged ≤6 years died in the nine incidents. Eighteen children underwent autopsies. The cause of death for all children was either hyperthermia or a combination of hyperthermia and asphyxia. Three of the nine incidents occurred during the summer of 1998 and accounted for 11 (58%) of the 19 deaths. Eight incidents occurred when outside ambient temperatures were at least 90 F (32.2 C) (Table 1), and at least five (56%) of the cars involved were parked in direct sunlight.

The method of trunk entry varied among the nine incidents. In two incidents, children found the keys to their parents' cars and opened the trunks. In two other incidents, children entered trunks without using a key—either a driver's side trunk-release lever or a manual release on the trunk itself was present. In one additional incident, four children climbed into an open trunk. The method of trunk entry could not be determined for the remaining four incidents. At least 15 children died in cars parked either at their own houses or at a relative's or neighbor's house. In three incidents, a dead child was alone in the trunk. In one incident, one 3-year-old child survived, and a 4-year-old child died. In six incidents, children were missing approximately $1-2\frac{1}{2}$ hours. In two other incidents, they were missing for 5–8 hours.

Reported by: AP Hart, MD, RE Zumwalt, MD, PJ McFeeley, MD, Office of the Medical Investigator, Univ of New Mexico School of Medicine, Albuquerque, New Mexico. B Marchant, TC Grey, MD, Office of the Medical Examiner, Salt Lake City, Utah. G Rohanna, Greene County Coroner's Office, Greene County, Pennsylvania. E Darby, Cherokee County Coroner's Office, Cherokee County, Georgia. S Hill, Riverside County Coroner's Office, Riverside County, California. M Day, Macon County Coroner's Office, Macon County, Illinois. Surveillance and Programs Br, and Health Studies Br, Div of Environmental Hazards and Health Effects, National Center for Environmental Health; and an EIS Officer, CDC.

Editorial Note: Although heat-related deaths in the United States have been described previously (2,3), the number and characteristics of car trunk entrapment-related

Fatal Car Trunk Entrapment — Continued

TABLE 1. Selected characteristics of deaths associated with car trunk entrapments among children, by year — United States, 1987–1998

Year	No. children	Age (yrs)	Month	Cause of death*	Outside temperature [†]	Time missing (hrs)
1987	1	4	July	§	101 F (38.3 C)	8
1987	1	3	August	Hyperthermia	91 F (32.7 C)	2
1989	1	5	June	§	106 F (41.1 C)	21/2
1993	2	3,5	July	Hyperthermia/ Asphyxiation¶	97 F (36.1 C)	8
1994	1	4	August	Hyperthermia	101 F (38.3 C)	1
1995	2	3,4	May	Hyperthermia/ Asphyxiation Hyperthermia/	90 F (32.2 C)	2
1998	4	2,3,5,5	July	Asphyxiation Hyperthermia/	90 F (32.2 C)	2
1998	2	2,5	August	Asphyxiation	85 F (29.4 C)	5
1998	5	2,3,5,6,6	August	Hyperthermia	100 F (37.7 C)	2

^{*}Medical examiners/coroners provided written and verbal cause-of-death information.

deaths have not been described, and the identified cases probably represent a minimum number of such deaths. No surveillance system exists to detect or report car trunk entrapment-related deaths, and no *International Classification of Diseases, Ninth Revision*, external cause-of-injury code exists for deaths associated with car trunk entrapments.

Heatstroke (hyperthermia) is a medical emergency and is often fatal despite medical care (4). Heatstroke is usually designated when a rectal or core temperature reaches 105 F (40.6 C) (4,5). The car trunk entrapment-related deaths described in this report were mainly heat related—no deaths were identified that occurred when the outside temperature was <85 F (<29.5 C), and all causes of death included hyperthermia.

Cars parked in direct sunlight can reach internal temperatures up to 131 F–172 F (55 C–78 C) when outside temperatures are 80 F–100 F (27 C–38 C) (6,7). Cars that are parked in direct sunlight and that are poorly ventilated also reach higher temperatures more rapidly than cars that are parked in the shade or that have windows completely opened (7). Most temperature increases inside cars occur during the first 15 minutes of being left in the sun (8). In at least two incidents during the summer of 1998, deaths occurred in dark cars, and the dark color probably contributed to the intense heat in the trunks (6).

The major mechanism for heat loss by the body in high ambient temperatures is evaporation (7). This mechanism is quickly defeated in the rising humidity of closed car trunks. Younger children are more sensitive to heat than older children and adults and are at greater risk for heatstroke (5). In addition to heatstroke, asphyxia was listed as a contributing cause of death in four of the seven incidents for which ME/C data were obtained. The combination of high temperature, humidity, and poor ventilation all contribute to the extreme danger of car trunks (7).

[†]Outside temperatures are approximated.

[§]Data were not available.

Information was available only for the 3-year-old.

Fatal Car Trunk Entrapment — Continued

The findings in this report are subject to at least three limitations. First, because LEXIS-NEXIS may exclude cases in areas with minimal media coverage, may overlook cases that are not in the database because of search technique, and does not contain all newspapers in the country, the total number of cases identified may be underestimated. Second, because primary source ME/C data were not obtained for two incidents, information accuracy in media reports used for analysis is unknown. Third, because autopsy findings are often minimal or nonspecific, determining cause of death for these types of deaths is largely dependent on the circumstances and a thorough examination of the death scene.

State and local public health officials can use the findings in this report to guide prevention messages about children playing in or around car trunks. Effective public health strategies to prevent deaths associated with car trunk entrapments should include 1) preventing children's access to car keys; 2) keeping cars locked, with trunks closed, when cars are not in use; and 3) supervising young children closely when they are around cars.

References

- 1. LEXIS-NEXIS [database online]. Dayton, Ohio: Reed Elsevier, 1998.
- 2. CDC. Heat-wave-related mortality Milwaukee-Wisconsin, July 1995. MMWR 1995;45:505-7.
- 3. CDC . Heat-related mortality—United States. MMWR 1998;47:473-6.
- 4. DiMaio DJ, DiMaio VJM. Forensic Pathology. Boca Raton, Florida: CRC Press, 1993:377-84.
- 5. Kilbourne EM. Heat waves and hot environments. Noji EK, ed. The public health consequences of disasters. New York, New York: Oxford University Press, 1997:245–69.
- 6. Zumwalt RE, Petty CS, Holman W. Temperature in closed automobiles in hot weather. Forensic Sci Gazette 1976;7:7–8.
- 7. Surpure J. Heat-related illness and the automobile. Annals of Emergency Medicine 1982;11:263–5.
- 8. Roberts KB, Roberts EC. The automobile and heat stress. Pediatrics 1976;58:101-4.

Forecasted State-Specific Estimates of Self-Reported Asthma Prevalence — United States, 1998

Asthma is a chronic inflammatory disorder of the lungs characterized by episodic and reversible symptoms of airflow obstruction (1). During 1993–1994, an estimated 13.7 million persons in the United States reported having asthma, and from 1980 to 1994 the prevalence of self-reported asthma in the United States increased 75% (2). Despite this increase, surveillance data are limited for asthma at the state and local levels (3). To estimate the 1998 prevalence rate of asthma for each state, CDC analyzed national self-reported asthma prevalence data from 1995. This report summarizes the results of the analyses, which project that approximately 17 million persons in the United States have asthma.

For this analysis, persons were considered to have asthma if they had had asthma diagnosed by a physician at some time in their life and had reported symptoms of asthma during the preceding 12 months. Using methods that have been applied elsewhere to forecast cancer rates (4), state-specific asthma prevalence estimates for 1998 were calculated using a three-step procedure: 1) race-, sex-, and age-specific asthma prevalence rates were calculated for each of the four U.S. census regions using data from the 1995 National Health Interview Survey (NHIS); 2) each state's 1998

Self-Reported Asthma Prevalence — Continued

demographic composition as estimated by the Bureau of Census was multiplied by the corresponding regional prevalences; and 3) linear extrapolations of region-specific increases in asthma prevalence from 1980 to 1994 were applied to the 3-year period from 1995 to 1998 for each state. Confidence intervals and relative standard errors for all estimates were calculated using regression parameters provided by CDC's National Center for Health Statistics for prevalence of chronic conditions (5).

In 1998, asthma affected an estimated 17,299,000 persons in the United States. The state with the largest estimated number of persons with asthma was California (2,268,300), followed by New York (1,236,200) and Texas (1,175,100) (Table 1). State-specific prevalence rates ranged from 5.8% to 7.2%. Differences in asthma prevalence rates between states were not significant. By region, 1-year period prevalence estimates ranged from 6.4% to 6.8% in the Northeast, 5.8% to 6.1% in the South, 6.6% to 6.7% in the Midwest, and 6.0% to 7.2% in the West.* The narrow range of prevalence rates within each of these regions indicates that state-specific differences in demographic composition minimally influenced estimated asthma prevalence.

Reported by: S Rappaport, MPH, B Boodram, MPH, Epidemiology and Statistics Unit, American Lung Association, New York City. Air Pollution and Respiratory Health Br, Div of Environmental Hazards and Health Effects, National Center for Environmental Health; and an EIS Officer, CDC.

Editorial Note: The findings in this report project state-specific prevalence rates of 5.8% to 7.2%. These findings are consistent with those from a study in Oregon, which estimated asthma prevalence at 6%–7% (6). However, surveys of self-reported asthma prevalence in Bogalusa, Louisiana (7), Chicago, Illinois (8), and Bronx, New York (9) all indicated estimates considerably higher than those in this report. State program planners can use these findings to estimate the burden of asthma within their states.

The findings in this report are subject to at least two limitations. First, the findings assume a linear growth in asthma prevalence since 1995. Although this linear assumption was selected after review of regional growth trends in asthma prevalence during the preceding 15 years (2), changes in the trends of self-reported asthma rates that may have occurred in the 3-year interval during 1995–1998 could not be captured by these linear extrapolations. Second, these results are based on the assumption that age, sex, and race-specific rates of asthma do not vary within any of the four geographic regions of the United States. Each state's estimated prevalence reflects its regional placement in the United States and its demographic composition. These analyses do not account for differences among states in the relative presence or absence of environmental risk factors in asthma prevalence, possible differences in genetic susceptibility toward the condition, or other sociodemographic indicators (e.g., poverty status). As a result, these findings underestimate the variability in asthma prevalence between states within regions. They also do not accurately represent asthma prevalence in geographic subpopulations within states.

^{*}Northeast=Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest=Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South=Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West=Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

Self-Reported Asthma Prevalence — Continued

TABLE 1. Forecasted estimates of self-reported asthma prevalence*, by state — United States, 1998

		Fatimenta d		
Region/State	No. cases	Estimated prevalence	(95% CI [†])	Standard error
Northeast				
Connecticut	215,900	6.6%	(5.6%-7.5%)	7.2%
Maine	80,300	6.4%	(5.4%-7.4%)	7.8%
Massachusetts	401,000	6.5%	(5.6%–7.5%)	7.2%
New Hampshire	78,500	6.6%	(5.5%–7.6%)	7.8%
New Jersey	540,400	6.7%	(5.7%–7.6%)	7.2%
New York	1,236,200	6.8%	(5.8%–7.8%)	7.3%
Pennsylvania	800,900	6.6%	(5.6%–7.5%)	7.2%
Rhode Island	64,400	6.5%	(5.5%–7.4%)	7.3%
Vermont Total	39,500	6.5% 6.7%	(5.5%–7.6%) (5.7%–7.6%)	7.8% 7.3%
	3,241,200	0.7%	(5.7%-7.6%)	7.3%
Midwest lowa	100 100	C C0/	/E GO/ 7 GO/ \	7 50/
Illinois	190,100 795,200	6.6% 6.7%	(5.6%–7.6%) (5.7%–7.6%)	7.5% 7.5%
Indiana	398,400	6.7%	(5.7%–7.0%)	7.3%
Kansas	174,900	6.7%	(5.7%–7.7%)	7.3%
Michigan	642,300	6.7%	(5.7%–7.7%)	7.5%
Minnesota	318,600	6.7%	(5.8%–7.7%)	7.1%
Missouri	362,300	6.1%	(4.7%–7.4%)	11.3%
Nebraska	112,100	6.7%	(5.7%–7.7%)	7.4%
North Dakota	43,600	6.7%	(5.7%–7.6%)	7.3%
Ohio	748,200	6.7%	(5.7%–7.6%)	7.4%
South Dakota	51,000	6.7%	(5.8%–7.7%)	7.3%
Wisconsin	350,800	6.7%	(5.7%–7.7%)	7.2%
Total	4,187,600	6.6%	(5.6%–7.6%)	7.4%
South				
Alabama	280,500	6.0%	(4.8%–7.1%)	9.5%
Arkansas	162,600	5.9%	(4.9%–6.9%)	6.9%
District of Columbia	31,400	5.9%	(3.6%–8.2%)	19.7%
Delaware	44,300	5.9%	(4.9%–6.9%)	8.5%
Florida	863,900	5.8%	(4.9%–6.8%)	8.0%
Georgia	458,700	6.0%	(4.9%–7.2%)	9.7%
Kentucky	232,800	5.9%	(4.9%–6.9%)	8.2%
Louisiana	265,500	6.1%	(4.8%–7.3%)	10.5%
Maryland	307,300	6.5%	(5.6%–7.5%)	7.2%
Mississippi	167,900	6.1%	(4.7%–7.4%)	11.3% 8.9%
North Carolina Oklahoma	447,200 191,700	5.9% 5.8%	(4.9%–7.0%) (4.8%–6.7%)	7.9%
South Carolina	228,600	6.0%	(4.8%–7.2%)	10.1%
Tennessee	328,300	5.9%	(4.9%–6.9%)	8.3%
Texas	1,175,100	6.0%	(5.0%–7.0%)	8.2%
Virginia	403,400	5.9%	(4.9%–6.9%)	8.6%
West Virginia	108,600	5.8%	(4.9%–6.8%)	8.2%
Total	5,697,800	5.9%	(4.9%–7.0%)	8.8%
West				
Alaska	42,500	6.7%	(5.7%–7.7%)	7.7%
Arizona	316,200	6.9%	(6.0%–7.9%)	6.9%
California	2,268,300	7.1%	(6.1%-8.0%)	6.8%
Colorado	283,700	7.1%	(6.1%–8.0%)	6.8%
Hawaii	73,100	6.0%	(4.1%–7.8%)	15.3%
ldaho	86,100	6.7%	(5.7%–7.8%)	7.6%
Montana	61,600	6.6%	(5.7%–7.6%)	7.4%
Nevada	125,700	7.2%	(6.3%–8.1%)	6.4%
New Mexico	121,800	6.8%	(5.8%–7.8%)	7.2%
Oregon	225,900	6.9%	(5.9%–7.8%)	6.9%
Utah	141,200	6.7%	(5.6%–7.8%)	8.1%
Washington Total	391,900 4,172,400	6.9% 7.0%	(5.9%–7.8%) (6.0%–8.0%)	6.8% 7.0%
Total	17,299,000	6.4%	(5.5%–7.5%)	7.8%

^{*}Persons were considered to have asthma if they had had asthma diagnosed by a physician at some time in their life and had reported symptoms of asthma during the preceding 12 months.

[†]Confidence interval.

Self-Reported Asthma Prevalence — Continued

Asthma is the ninth leading cause of hospitalization nationally (10). Its severity can be managed with appropriate medical treatment, education, and environmental modification (1). However, fewer than 10 states have conducted asthma prevalence surveys. The initiation of state-based asthma control and management programs will require better state and local data on asthma prevalence to evaluate the effectiveness of these programs. State-level surveillance could incorporate existing data such as hospital discharge data and managed-care data. Questions about asthma could also be added to state and community-level surveys such as the State and Local Integrated Telephone Survey and other surveys conducted in individual states such as the Behavioral Risk Factor Surveillance System.

State-based surveys should include questions related to asthma diagnosis, severity, management techniques, and known geographic and household risk factors. These surveillance data will provide a foundation for planning and evaluating asthmacontrol programs, identifying high-risk and hard-to-access populations, and structuring health promotion and education initiatives.

References

- 1. National Institutes of Health. Practical guide for the diagnosis and management of asthma. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health. (Publication no. 97-4053).
- 2. CDC. Surveillance for asthma—United States, 1960-1995. MMWR 1998;47(no. SS-1).
- 3. Brown CM, Anderson HA, Etzel RA. Asthma: the states' challenge. Public Health Reps 1997;112:198–205.
- 4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–9.
- CDC. Vital and health statistics: design and estimation for the National Health Interview Survey. Washington, DC: US Department of Health and Human Services, CDC, National Center for Health Statistics, 1989; DHHS publication no. (PHS) 89-1384. (Series 2, no. 110).
- 6. Ertle AR, London MR. Insights into asthma prevalence in Oregon. J Asthma 1998;35:281-9.
- 7. Farber HJ, Wattigney W, Berenson G. Trends in asthma prevalence: The Bogalusa Heart Study. Ann Allergy Asthma Immunol 1997;78:265–9.
- 8. Persky VW, Slezak J, Contreras A, et al. Relationships of race and socioeconomic status with prevalence, severity, and symptoms of asthma in Chicago school children. Ann Allergy Asthma Immunol 1998;81:266–71.
- 9. Crain EF, Weiss KB, Bijur PE, Hersh M, Westbrook L, Stein RE. An estimate of the prevalence of asthma and wheezing among inner-city children. Pediatrics 1994;94:356-62.
- CDC. National Hospital Discharge Survey: annual summary, 1995. Washington, DC: US Department of Health and Human Services, CDC; DHHS publication no. (PHS) 98-1794. (Series 13, no. 133).

Abortion Surveillance: Preliminary Analysis — United States, 1996

For 1996, CDC compiled data about legal induced abortions from the 50 states, New York City, and the District of Columbia. The total number of legal induced abortions was available from all reporting areas; however, not all areas collected information about the characteristics of women who obtained abortions. This report presents preliminary data for 1996; final abortion data for 1996 will be published during spring 1999.

In 1996, a total of 1,221,585 legal induced abortions were reported to CDC (Table 1), a slight increase of 0.9% from the number reported for 1995 (1). The number of live births decreased slightly by 0.2% during the same period (2). From 1995 to 1996, the

TABLE 1. Reported number of legal induced abortions, abortion ratios,* abortion rates,† and characteristics of women who obtained legal induced abortions, by year — United States, selected years, 1972–1996

Characteristic	1972	1976	1980	1985	1990	1991	1992	1993	1994	1995	1996§
Reported no. legal abortions Abortion ratio Abortion rate	586,760 180 13	988,267 312 21	1,297,606 359 25	1,328,570 354 24	1,429,577 345 24	1,388,937 339 24	1,359,145 335 23	1,330,414 334 22	1,267,415 321 21	1,210,883 311 20	1,221,585 314 20
	15	21	25	24		tage distrib		22	21	20	20
Residence					reiteii	tage distrib	oution.				
In-state	56.2	90.0	92.6	92.4	4 91.8	91.6	92.0	91.4	91.5	91.7	91.9
Out-of-state	43.8	10.0									
Age group (yrs)	43.0	10.0	7.4	, ,,,	0.2	. 0	. 0.0	0.0	0.0	, 0.0	0.1
1190 gloup (ylo) ≤19	32.6	32.1	29.2	26.3	3 22.4	21.0	20.1	20.0	20.2	20.1	20.3
20–24	32.5	33.3									
≥25	34.9	34.6									
Race	34.9	34.0	ა ან.ა	39.0	7 44.2	44.0	45.4	45.0	40.3	47.4	47.0
White	77.0	66.6	69.9	66.6	64.8	3 63.8	8 61.5	60.9	60.5	59.5	5 59.1
Black	23.0	33.4									
Other**	23.0	33.4	- 30.1 —	3.5							
	_	_	_	3.0	5 5.5	5.7	4.0	4.2	. 4.0	5.0	5.7
Ethnicity Hispanic					0.0	10.5	. 15.0	147	. 145	. 15/	101
Non-Hispanic	_	_	_	_	9.8 90.2						
Marital status	_	_	_	_	30.2		04.0	00.3	05.0	04.0	00.5
Married	20.7	04.0		10.1	04-	. 01			10.0	10 -	
Unmarried	29.7	24.6									
	70.3	75.4	76.9	80.7	7 78.3	78.6	5 79.2	79.6	80.1	80.3	79.9
No. live births ^{††}											
0	49.4	47.7									
1	18.2	20.7									
2	13.3	15.4									
3 ≥4	8.7	8.3									
	10.4	7.9	3.2	2.5	5 3.4	3.4	3.5	3.3	3.4	3.5	3.6
Type of procedure											
Curettage	88.6	92.8									
Suction	65.2	82.6									
Sharp	23.4	10.2	5.7	2.9	9 2.8	3 1.6	3 1.9	2.6	2.6	3 2.3	3 2.3
Intrauterine instillation											
Other§§	10.4	6.0									
Others	1.0	1.2	1.4	0.8	3 0.4	l 0.4	1 0.4	0.4	0.4	0.6	0.8

Weeks' gest	at	ÌΟ	r
-------------	----	----	---

Weeks' gestation											Ą
≤8	34.0	47.0	51.7	50.3	51.6	52.3	52.1	52.3	53.7	54.0	54.6
≤ 6	_		_	_	_	_	14.3 ^{¶¶}	14.7***	15.7 ^{†††}	15.7 ^{†††}	16.4 ^{§§§} 5.
7	_	_	_	_	_	_	15.6 ^{¶¶}	16.2***	16.5 ^{†††}	17.1 ^{†††}	17.4 ^{§§§} 5
8	_	_	_	_	_	_	22.2 ^{¶¶}	21.6***	21.6 ^{†††}	21.2 ^{†††}	20.9§§§ 🛇
9–10	30.7	28.1	26.2	26.6	25.3	25.1	24.2	24.4	23.5	23.1	22.6
11–12	17.5	14.4	12.2	12.5	11.7	11.5	12.0	11.6	10.9	10.9	11.0 🖺
13–15	8.4	4.5	5.1	5.9	6.4	6.1	6.0	6.3	6.3	6.3	6.0 <i>a</i>
16–20	8.2	5.1	3.9	3.9	4.0	3.9	4.2	4.1	4.3	4.3	4.3
≥21	1.2	0.9	0.9	0.8	1.0	1.1	1.5	1.3	1.3	1.4	1.5
* Number of legal induced abortions per 1000 live births. † Number of legal induced abortions per 1000 women aged 15–44 years. § Preliminary data. The number of areas reporting a given characteristic varied. For 1996, the number of areas reporting residence was 45; age, 45; race, 35; ethnicity, 23; marital status, 34; number of live-born infants, 39; type of procedure, 41; and weeks of gestation, 40. ¶ Percentage distributions are based on known values in data from all areas reporting a given characteristic, except where the proportion of unknown values exceeded 15%.											

values exceeded 15%.

*** Reported as "other" race.

†† For years 1972 and 1976, data indicate number of living children.

§§ Includes hysterotomy and hysterectomy and procedures reported as "other."

Data are for 36 of 39 areas reporting weeks of gestation.

*** Data are for 38 of 41 areas reporting weeks of gestation.

††† Data are for 38 of 40 areas reporting weeks of gestation.

§§§ Data are for 37 of 40 areas reporting weeks of gestation.

Abortion Surveillance — Continued

number of reported abortions decreased in 26 of 52 reporting areas. From 1995 to 1996, the national abortion ratio (number of legal abortions per 1000 live births reported by all reporting areas) increased slightly, from 311 to 314, respectively (Table 1), and the national abortion rate (number of legal abortions per 1000 women aged 15–44 years) remained stable at 20. Consistent with previous years, approximately 92% of women who had legal abortions were residents of the state in which the procedure was performed.

Women who obtained legal induced abortions in 1996 were predominately white and unmarried. As in 1995, approximately 20% of women who obtained legal abortions in 1996 were aged ≤19 years; 32% were aged 20–24 years. Curettage (suction and sharp) remained the primary abortion procedure (99% of all procedures). As in previous years, more than half of legal abortions (55%) were performed during the first 8 weeks of gestation; specifically, 16% were at ≤6 weeks; 17% at 7 weeks; and 21% at 8 weeks. Approximately 88% of abortions were performed during the first 12 weeks of pregnancy.

Reported by: Surveillance Unit, Statistics and Computer Resources Br, Div of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: From 1980 to 1990, the number of legal induced abortions in the United States varied by ≤5% annually and increased overall by 10% (1). However, from 1990 (the year in which the number of abortions was highest) to 1995, the number of reported abortions decreased by 15%. In 1996, the number increased slightly by 0.9%.

During 1972–1980, the national legal abortion rate increased each year; during 1980–1992, the rate remained stable, then declined during 1992–1995. The 1996 abortion rate of 20 per 1000 women of reproductive age (i.e., aged 15–44 years) remained unchanged from 1995 and was the lowest rate recorded since 1975 (1,3).


From 1987 to 1995, the national ratio of abortions to live births steadily declined each year reaching the lowest level in 1995 for any year since 1975 (1,3). In 1996, despite an increase in the ratio, the ratio was still at its lowest recorded level since 1976 (1,4). The ratio increased in 1996 because the numerator of this ratio (the number of abortions) increased slightly, and the denominator (the number of live births) decreased slightly. Factors contributing to the decrease in the proportion of pregnancies that ended in abortion since 1990 include a reduction in the number of unintended pregnancies, attitudinal changes concerning the decision to have an abortion or to carry a pregnancy to term, and reduced access to abortion services (5–7).

The decline in the abortion ratios also may be attributed to a shift in the age distribution of reproductive-aged women obtaining abortions. Although the actual number of women of reproductive age in the United States has increased by 12% since 1980, the proportion who are older (i.e., in later, less fertile reproductive years) has increased (2). For example, from 1980 to 1996, the percentage of women of reproductive age who were aged <30 years (the age group having highest fertility) declined from 58% to 45%, respectively (Bureau of the Census, unpublished data, 1998), and the percentage of women aged 35–44 years (the age group having lowest fertility) increased from 25% to 37%, respectively.

During 1996, the total number of legal induced abortions were available for all 52 reporting areas. However, approximately 31% of abortions were reported from states that, in 1996, did not have centralized reporting of abortions (four states) or from states whose state health departments did not collect, and therefore could not pro-

(Continued on page 1035)

FIGURE I. Selected notifiable disease reports, comparison of provisional 4-week totals ending November 28, 1998, with historical data — United States



^{*}Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — provisional cases of selected notifiable diseases, United States, cumulative, week ending November 28, 1998 (47th Week)

	Cum. 1998		Cum. 1998
Anthrax Brucellosis Cholera Congenital rubella syndrome Cryptosporidiosis* Diphtheria Encephalitis: California* eastern equine* St. Louis* western equine* Hansen Disease Hantavirus pulmonary syndrome* Hemolytic uremic syndrome, post-diarrheal* HIV infection, pediatric*	52 12 3 2,920 1 82 3 24 - 100 19 78 230	Plague Poliomyelitis, paralytic Psittacosis Rabies, human Rocky Mountain spotted fever (RMSF) Streptococcal disease, invasive Group A Streptococcal toxic-shock syndrome* Syphilis, congenital [¶] Tetanus Toxic-shock syndrome Trichinosis Typhoid fever Yellow fever	8 1 46 - 308 1,891 46 361 34 122 12 299

^{-:} no reported cases

^{*}Not notifiable in all states.

^{*}Not notifiable in all states.

† Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).

† Updated monthly from reports to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP), last update October 25, 1998.

† Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 1998, and November 22, 1997 (47th Week)

					coli O	erichia 157:H7			Нера	
	All Cum.	Cum.	Chlai Cum.	mydia Cum.	NETSS [†] Cum.	PHLIS§ Cum.	Gono Cum.	rrhea Cum.	C/NA Cum.	A,NB Cum.
Reporting Area	1998*	1997	1998	1997	1998	1998	1998	1997	1998	1997
UNITED STATES	38,924	51,445	492,859	424,676	2,736	1,782	297,085	268,538	4,521	3,147
NEW ENGLAND Maine	1,539 26	2,235 50	16,518 959	16,330 906	314 35	246	4,698 61	5,395 61	88	52 -
N.H.	28	39	860	735	43	43	81	86	-	-
Vt. Mass.	18 785	32 803	378 7,588	386 6,650	19 144	17 142	34 2,077	47 1,915	3 82	3 42
R.I.	108 574	133	2,060	1,835	12 61	1	371	396	3	7
Conn. MID. ATLANTIC	10,425	1,178 15,287	4,673 54,604	5,818 51,706	274	43 70	2,074 33.433	2,890 34,684	334	- 287
Upstate N.Y.	1,249	2,371	· N	N	206	-	6,027	5,868	249	214
N.Y. City N.J.	5,885 1,909	8,011 3,044	31,564 9,954	24,928 9,125	8 60	12 48	14,164 6,998	13,153 6,875	-	-
Pa.	1,382	1,861	13,086	17,653	N	10	6,244	8,788	85	73
E.N. CENTRAL Ohio	2,741 562	3,819 786	80,271 22,949	57,929 20,387	422 115	305 61	58,023 14.997	37,347 13,344	460 8	499 18
Ind.	448	483	4,656	8,516	94	47	4,477	5,568	7	12
III. Mich.	1,044 531	1,517 800	24,415 18,875	U 18,952	105 108	58 62	20,274 14,220	U 13,965	32 413	84 360
Wis.	156	233	9,376	10,074	N	77	4,055	4,470	-	25
W.N. CENTRAL Minn.	754 146	1,039 191	27,940 5,743	29,661 6,070	458 191	375 197	14,393 2,201	13,068 2,138	266 10	58 4
lowa	60	93	2,063	3,943	93	56	660	1,012	8	27
Mo. N. Dak.	367 5	509 10	10,936 849	10,996 794	45 11	60 15	8,120 71	6,742 66	241	10 3
S. Dak. Nebr.	15 59	8 84	1,418 2,364	1,254 2,432	33 54	34	207 960	151 1,072	4	2
Kans.	102	144	4,567	4,172	31	13	2,174	1,887	3	12
S. ATLANTIC	10,118	12,835	101,191	85,207	246	146	83,159	83,986	169	228
Del. Md.	122 1,400	210 1,798	2,354 6,619	49 6,765	35	2 14	1,387 8,638	1,164 10,424	15	10
D.C. Va.	751 771	978 1,096	N 11,750	N 10,695	1 N	42	3,163 8,169	4,011 7,958	- 11	- 25
W. Va.	72	108	2,355	2,654	12	7	744	840	6	16
N.C. S.C.	704 640	764 704	20,065 14,761	15,743 11,327	54 17	46 9	17,266 9,335	15,703 10,420	20 9	47 37
Ga. Fla.	1,055 4,603	1,468 5,709	20,637 22,650	14,146 23,828	73 54	- 26	17,198 17,259	16,502 16,964	9 99	93
E.S. CENTRAL	1,598	1,859	35,095	32,079	111	39	34,516	32,095	181	327
Ky. Tenn.	249 591	340 717	5,834 12,078	5,695 11,551	32 53	33	3,390 10,508	3,662 10,121	19 155	13 217
Ala.	417	511	9,150	7,763	23	2	11,714	10,850	5	11
Miss.	341	291	8,033	7,070	3	4	8,904	7,462	2 398	86
W.S. CENTRAL Ark.	4,758 177	5,608 216	68,112 3,607	60,578 2,518	115 11	24 10	41,872 3,607	39,598 4,264	398 10	460 14
La. Okla.	819 256	975 274	13,684 8,611	9,098 6,669	5 23	7 7	11,720 4,796	8,862 4,334	103 14	207 7
Tex.	3,506	4,143	42,210	42,293	76	-	21,749	22,138	271	232
MOUNTAIN Mont.	1,360 26	1,540 40	29,537 1,205	27,113 1,086	337 15	217	8,285 44	7,416 55	335 7	289 21
ldaho	27	50	1,848	1,489	38	23	158	137	87	65
Wyo. Colo.	3 254	14 366	626 7,385	542 6,654	53 89	55 64	29 2,075	47 2,084	66 33	72 31
N. Mex.	189	164	3,491	3,460	19	13	839	784	92	56
Ariz. Utah	549 114	375 132	10,243 1,973	9,737 1,588	21 80	26 21	3,717 207	3,318 249	8 23	25 5
Nev.	198	399	2,766	2,557	22	15	1,216	742	19	14
PACIFIC Wash.	5,631 375	7,223 570	79,591 9,672	64,073 8,377	459 104	360 104	18,706 1,742	14,949 1,753	2,290 22	947 25
Oreg. Calif.	146 4,949	261 6,257	5,434 60,719	4,499 48,184	100 248	94 147	792 15,470	672 11,724	5 2,208	3 758
Alaska	17	43	1,603	1,387	7	-	266	339	1	-
Hawaii	144 1	92 2	2,163 201	1,626 193	N N	15	436 24	461 27	54	161
Guam P.R.	1,499	1,716	U	U	N 6	Ū	342	499	-	-
V.I. Amer. Samoa	31 -	94	N U	N U	N N	U U	U U	U U	U U	U U
C.N.M.I.	-	1	Ň	Ň	N	Ü	28	22	-	2

N: Not notifiable U: Unavailable

^{-:} no reported cases

C.N.M.I.: Commonwealth of Northern Mariana Islands

^{*}Updated monthly from reports to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, last update October 25, 1998.

†National Electronic Telecommunications System for Surveillance.

§Public Health Laboratory Information System.

TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 1998, and November 22, 1997 (47th Week)

	Legion	nellosis		me ease	Mai	laria	Syp (Primary &		Tubero	culosis	Rabies, Animal
Reporting Area	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
	1998	1997	1998	1997	1998	1997	1998	1997	1998*	1997	1998
UNITED STATES	1,175	973	11,733	11,114	1,233	1,681	6,370	7,626	12,979	15,970	6,195
NEW ENGLAND	77	77	2,538	2,848	55	79	69	124	410	398	1,318
Maine	1	3	11	8	5	1	1	2	10	18	202
N.H.	7	7	44	36	5	8	2	-	12	15	74
Vt.	7	12	11	8	1	2	4		4	5	61
Mass.	30	27	704	284	16	30	42	62	229	226	470
R.I.	19	11	603	380	10	7	1	2	50	31	88
Conn.	13	17	1,165	2,132	18	31	19	58	105	103	423
MID. ATLANTIC	284	214	7,743	6,478	312	479	243	362	2,729	2,851	1,437
Upstate N.Y.	99	66	3,841	2,691	87	67	35	36	354	401	1,000
N.Y. City	27	23	28	168	147	296	72	79	1,352	1,447	U
N.J.	15	28	1,599	1,795	49	83	78	145	562	611	202
Pa.	143	97	2,275	1,824	29	33	58	102	461	392	235
E.N. CENTRAL	375	320	158	570	118	152	987	584	1,109	1,573	127
Ohio	124	114	81	37	15	18	124	196	87	236	55
Ind.	112	52 33	57 8	33 13	11 36	16 60	210 424	162 U	101 564	137 823	11 16
Mich.	75	82	12	27	47	42	176	128	339	264	35
Wis.	32	39	U	460	9	16	53	98	18	113	10
W.N. CENTRAL	72	56	192	149	90	57	117	163	360	500	640
Minn.	8	3	157	110	55	28	9	16	133	134	112
lowa Mo.	10 24	9 20	22 2	6 26	8 15	26 9 11	- 88	7 107	43 93	46 209	139 25
N. Dak. S. Dak.	- 3	2 2 2	-	- 1	2	3	- 1	- 1	8 17	12 10	131 143
Nebr.	19	15	3	2 4	1	1	6	3	27	20	7
Kans.	8	5	8		9	4	13	29	39	69	83
S. ATLANTIC	135	113	811	727	297	301	2,353	3,175	1,788	3,044	1,780
Del.	13	11	40	109	3	5	20	22	18	32	30
Md.	28	19	567	462	85	79	599	836	255	282	416
D.C. Va. W. Va.	7 20 N	4 25 N	4 65 12	9 62 10	18 53 2	19 64 1	73 137 3	102 220 3	93 250 38	91 275 49	519 70
N.C.	14	14	54	32	27	18	675	899	409	374	136
S.C.	10	8	7	2	6	17	305	333	214	304	140
Ga.	8	1	5	7	37	46	255	484	441	542	272
Fla.		31	57	34	66	52	286	276	70	1,095	197
E.S. CENTRAL	59	53	85	86	30	36	1,101	1,545	961	1,174	251
Ky. Tenn.	25 22 5	11 31	24 42	16 39 10	6 16 6	12 8 10	100 510	123 672	152 341	167 412	30 132
Ala. Miss.	7	4 7	17 2	21	2	6	262 229	379 371	302 166	380 215	87 2
W.S. CENTRAL	39	33	24	89	28	54	932	1,194	1,836	2,297	135
Ark.		2	6	25	1	5	100	149	136	171	31
La.	4	6	4	3	15	13	394	331	255	199	104
Okla.	12	2	2	26	4	8	113	112	147	186	
Tex.	23	23	12	35	8	28	325	602	1,298	1,741	
MOUNTAIN	72	62	22	12	61	65	211	163	393	500	210
Mont. Idaho	2 2	1 2 1	5	3	1 8 -	2 - 2	2 1	1	18 13	16 11	51 -
Wyo. Colo. N. Mex.	1 17 2	18 3	1 5 4	3 - 1	19 12	30 8	11 22	15 8	4 U 63	2 76 60	63 39 6
Ariz.	19	12	1	2	8	11	160	124	182	207	19
Utah	22	18		1	1	3	4	5	48	28	26
Nev.	7	7	6	2	12	9	11	10	65	100	6
PACIFIC	62	45	160	155	242	458	357	316	3,393	3,633	297
Wash.	12	8	7	10	17	46	27	9	194	265	-
Oreg.	1	36	21	17	16	25	6	9	124	135	7
Calif.	47		131	126	201	373	322	296	2,884	3,011	267
Alaska Hawaii	1 1	1	1 -	2	3 5	3 11	1 1	1 1	46 145	66 156	23
Guam P.R.	2 	- -	- .:	- 	1 	5	1 168	228	36 68	13 184	49
V.I. Amer. Samoa	U U	U U	U U	U	U U	U U	U U 164	U U 11	U U 77	U U 17	U U
C.N.M.I.	-	-	-	-	-	-	164	11	77	17	-

N: Not notifiable

U: Unavailable

-: no reported cases

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending November 28, 1998, and November 22, 1997 (47th Week)

-	H. influ	ienzae,	Hepatitis (Viral), by type						Meas	les (Rubec	ola)	
		sive		4	E		Indi	genous	lmp	orted [†]		tal
Reporting Area	Cum. 1998*	Cum. 1997	Cum. 1998	Cum. 1997	Cum. 1998	Cum. 1997	1998	Cum. 1998	1998	Cum. 1998	Cum. 1998	Cum. 1997
UNITED STATES	928	973	19,898	25,788	7,821	8,610	1	61	-	25	86	129
NEW ENGLAND Maine	61 3	55 5	252 19	602 59	175 5	164 6	-	1	-	2	3	19 1
N.H.	9	10	14	33	18	16	-	-	-	-	-	1
Vt. Mass.	7 36	3 32	16 104	13 246	6 55	11 69	-	1	-	1 1	1 2	16
R.I. Conn.	5 1	3 2	16 83	126 125	66 25	14 48	-	-	-	-	-	1
MID. ATLANTIC	137	151	1,341	1,939	1,014	1,244	-	8	-	6	14	26
Upstate N.Y. N.Y. City	59 26	50 41	328 351	336 848	270 261	286 429	-	1	-	1 -	2	5 10
N.J. Pa.	46 6	42 18	307 355	284 471	176 307	226 303	-	7 -	-	1 4	8 4	3 8
E.N. CENTRAL	153	150	3,267	2,729	1,423	1,367	1	12	-	3	15	10
Ohio Ind.	46 39	81 14	280 310	289 298	72 718	79 94		2	-	1 1	1 3	-
III. Mich.	53 8	37 17	619 1,900	755 1,218	177 416	257 407	1 -	1 9	-	1	1 10	7 2
Wis.	7	1	158	169	40	530	-	-	-	-	-	1
W.N. CENTRAL Minn.	83 65	57 44	1,239 118	2,000 192	367 48	441 41	-	1 -	-	-	1 -	17 8
lowa Mo.	2 9	6 4	392 562	426 1,021	54 219	39 310	U	1 -	U	-	1 -	- 1
N. Dak. S. Dak.	-	2	3 31	10 23	4 2	5 1	-	-	-	-	-	- 8
Nebr.	1	1	39	86	14	16 29	-	-	-	-	-	-
Kans. S. ATLANTIC	6 179	- 152	94 1,827	242 1,844	26 1,043	1,113	-	3	-	5	8	14
Del. Md.	51	56	3 306	29 178	3 146	6 154	-	-	-	1	1	2
D.C.	-	-	54	32	11	29	Ū	-	Ū	-	-	1
Va. W. Va.	16 5	13 4	195 7	211 11	92 8	116 16	-	-	-	2	2	1
N.C. S.C.	24 3	21 4	115 38	187 98	215 42	235 90	-	-	-	-	-	2 1
Ga. Fla.	45 35	31 23	603 506	559 539	128 398	126 341	-	1 2	-	1 -	2 2	1 6
E.S. CENTRAL	53	54	340	567	365	659	-	-	-	2	2	1
Ky. Tenn.	7 31	8 30	22 207	68 344	41 255	36 411	-	-	-	1	1	-
Ala. Miss.	13 2	14 2	68 43	78 77	67 2	72 140	-	-	-	1 -	1 -	1 -
W.S. CENTRAL	54	47	3,756	5,274	1,133	1,179	-	1	-	-	1	8
Ark. La.	23	2 12	89 108	196 214	87 154	79 158	-	1	-	-	1	-
Okla. Tex.	28 3	30 3	552 3,007	1,326 3,538	92 800	47 895	-	-	-	-	-	1 7
MOUNTAIN	106	79	2,988	3,906	761	791	-	3	-	2	5	8
Mont. Idaho	1	1	93 227	68 125	5 42	12 50	-	-	-	-	-	-
Wyo. Colo.	1 18	4 18	36 319	31 377	8 105	24 134	-	-	-	-	-	-
N. Mex. Ariz.	7 54	8 29	137 1,789	324 2,058	295 166	235 183	-	3	-	2	- 5	- 5
Utah	6	3	183	521	66	84	-	-	-	-	-	1
Nev. PACIFIC	19 102	16 228	204 4,888	402 6,927	74 1,540	69 1,652	-	32	-	- 5	- 37	2 26
Wash. Oreg.	10 37	5 32	884 355	595 344	111 114	73 108	-	-	-	1	1	2
Calif.	47	175	3,595	5,812	1,297	1,447	-	5	-	3	8	20
Alaska Hawaii	1 7	8 8	18 36	33 143	12 6	14 10	-	27 -	-	1 -	28 -	4
Guam P.R.	2	-	49	- 259	2 333	3 748	U	-	U	-	-	-
V.I.	U	U	U	U	U	U	U	U	U	U	Ų	Ü
Amer. Samoa C.N.M.I.	U -	U 6	U 3	U 1	U 53	U 44	U	U -	U	U -	U -	U 1

N: Not notifiable

U: Unavailable

^{-:} no reported cases

 $^{^*}$ Of 216 cases among children aged <5 years, serotype was reported for 106 and of those, 42 were type b. † For imported measles, cases include only those resulting from importation from other countries.

TABLE III. (Cont'd.) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending November 28, 1998, and November 22, 1997 (47th Week)

		ococcal ease		Mumps			Pertussis			Rubella	
Reporting Area	Cum. 1998	Cum. 1997	1998	Cum. 1998	Cum. 1997	1998	Cum. 1998	Cum. 1997	1998	Cum. 1998	Cum. 1997
UNITED STATES	2,375	2,888	5	434	586	71	5,526	5,056	-	328	158
NEW ENGLAND	100	181	-	7	12	7	850	922	_	38	1
Maine	6	17	-	-	-	-	5	19	-	-	-
N.H. Vt.	4 5	14 4	-	-	1 -	3 2	112 71	127 235	-	-	-
Mass. R.I.	52 8	89 20	-	4 1	4 6	-	608 9	499 16	-	8 1	1
Conn.	25	37	-	2	1	2	45	26	-	29	-
MID. ATLANTIC	226	316	2	31	55	8	526	372	-	130	34
Upstate N.Y. N.Y. City	65 23	83 51	2	8 4	11 3	8 -	290 23	152 60	-	111 14	6 28
N.J.	54	67	-	2	8	-	5	13	-	4	-
Pa. E.N. CENTRAL	84 353	115 441	- 1	17 72	33 80	6	208 591	147 555	-	1	6
Ohio	131	152	1	28	31	3	264	151	-	-	-
Ind. III.	63 86	51 136	-	6 11	12 11	3	140 105	55 93	-	-	2
Mich.	41	65	-	27	22	-	65	55	-	-	-
Wis.	32	37	-	-	4	-	17	201	-	-	4
W.N. CENTRAL Minn.	197 31	211 34	-	30 13	17 6	14 14	515 320	468 268	-	33	-
Iowa	40	44	U	11	9	U	68	92	U	-	-
Mo. N. Dak.	70 5	90 2	-	3 2	-	-	32 3	66 1	-	2	-
S. Dak. Nebr.	7 14	5 15	-	-	- 1	-	8 18	5 10	-	-	-
Kans.	30	21	-	1	1	-	66	26	-	31	-
S. ATLANTIC	421	494	-	48	71	1	309	403	-	19	78
Del. Md.	2 29	5 42	-	-	1	-	5 54	1 112	-	- 1	-
D.C.	1	12	U	-	-	U	1	3	U	-	1
Va. W. Va.	43 16	58 18	-	8 -	18 -	-	36 2	51 6	-	1 -	1 -
N.C. S.C.	56 55	87 52	-	11 7	10 11	-	98 27	115 28	-	13	59 15
Ga.	92	94	-	1	10	-	27	13	-	-	-
Fla.	127	126	-	21	21	1	59	74	-	4	2
E.S. CENTRAL Ky.	221 34	218 45	-	14 -	31 3	1 -	117 50	136 61	-	2	1 -
Tenn.	70	75	-	1	6	1	36	36	-	2	-
Ala. Miss.	93 24	73 25	-	8 5	9 13	-	28 3	28 11	-	-	1 -
W.S. CENTRAL	273	274	-	59	81	-	351	269	-	87	4
Ark. La.	30 58	32 48	-	12 10	1 14	-	91 9	51 19	-	-	-
Okla.	40	39	-	-	-	-	30	51	-	-	-
Tex.	145	155	-	37	66	-	221	148	-	87	4
MOUNTAIN Mont.	141 4	166 8	1 -	38	54 -	22	1,069 12	1,079 18	-	5 -	7 -
Idaho Wyo.	11 7	10 3	-	5 1	3 1	5	249 8	518 7	-	-	2
Colo.	30	44	-	6	3	1	220	342	-	-	-
N. Mex. Ariz.	25 41	29 39	N -	N 6	N 32	-	94 199	115 35	-	1 1	- 5
Utah	14	15	1	6	8	16	240	20	-	2	-
Nev.	9	18	-	14 125	7	-	47	24	-	1	-
PACIFIC Wash.	443 59	587 83	1 1	135 11	185 19	12 3	1,198 308	852 362	-	14 9	27 5
Oreg. Calif.	82 294	114 380	N -	N 99	N 133	1 8	87 774	46 410	-	3	14
Alaska	3	3	-	2	8	-	14	16	-	-	-
Hawaii	5	7	-	23	25	-	15	18	-	2	8
Guam P.R.	1 6	1 8	U -	2 1	1 7	U -	6	-	U -	-	-
V.I.	U	U	U	U	U	U	U	U	U	U	U
Amer. Samoa C.N.M.I.	U -	U -	U U	U 2	U 4	U U	U 1	U -	U U	U -	U -
							•				

N: Not notifiable

U: Unavailable

TABLE IV. Deaths in 122 U.S. cities,* week ending November 28, 1998 (47th Week)

	ı	All Cau	ıses, By	/ Age (Y	ears)		P&I [†]	P&I [†]		All Cau	ises, By	Age (Y	ears)		P&l [†]
Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn. Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Mass. New Haven, Conn. Providence, R.I. Somerville, Mass. Springfield, Mass. Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J.	34 57 5 31 32 67 2,356 37 22 94 23 6	385 103 33 9 166 28 15 2 41 2 24 42 55 52 1,702 24 19 68 13	28 7 1 1 7 2 5 4 11 431 7 3 15 6 1	29 10 1 1 - 1 2 - 1 4 5 1 1 2 1 1 4 5 - 1 1 2 1 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1	10 2 	9 2 1 - 2 - - 1 1 40 - 2 4	38 13 6 - 1 3 - 2 5 - 2 1 5 111 1 - 5 4 - 3	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Fla. Tampa, Fla. Washington, D.C. Wilmington, Del. E.S. CENTRAL Birmingham, Ala. Chattanooga, Tenn. Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Ala.	73 49 232 47 27	677 13 116 38 80 23 29 37 33 138 89 7 517 130 42 51 33 155	193 8 36 12 14 21 7 8 3 3 3 43 2 151 33 19 10 10 4 4 4	86 3 19 5 6 9 1 3 4 1 10 25 7 2 9 5 4 7 2 9 5 4 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	20 1 7 1 - - - 2 8 - 26 5 3 2 2 6 1 1	26 1 6 1 5 3 1 6 3 3 5 2 3 2 14 2 1	48 19 5 1 1 3 2 2 2 9 4 - 37 12 4 3 4 1 1
Erie, Pa. Jersey City, N.J. New York City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa. Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y. E.N. CENTRAL Akron, Ohio	U 16 300 53 26 80 23 26 41 24 26 U	25 10 1,063 U 225 42 23 62 20 24 31 18 21 U	2 302 U 5 43 8 3 12 3 1 7 4 4 U 337 8	102 102 U 1 21 2 2 3 3 - 1 1 1 1 U 137 3	1 23 U - 6 - 1 1 1 1 U 41 1	1 2 21 U 1 5 1 - - - - U 5 3 3	3 - 64 U - 13 6 3 6 3 - 1 2 - U 111 - 1	Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La. Corpus Christi, Tex. Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La. San Antonio, Tex. Shreveport, La. Tulsa, Okla. MOUNTAIN Albuquerque, N.M. Roise Idaho	116 55 50 343 46 27 136 73 86 787 59	54 703 29 21 35 60 30 35 232 34 14 103 45 65 563 49	23 227 11 8 11 27 13 11 67 10 9 25 20 15	19 87 4 6 1 16 8 3 3 6 1 5 6 3 1	6 22 2 3 4 1 5 2 2 2	28 4 9 3 1 3 2 2 16	2 72 5 - 1 4 1 7 28 4 - 11 4 7 5 9 3
Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Micl Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohio	34 461 119 143 162 78 120 20 69 3 1. 62 125 27 91 46 39 75 53	28 284 87 91 112 58 66 17 54 42 82 23 61 34 30 35 63	94 13 31 32 15 28 3 10 1 11 27 2 21 10 6 2	3 14 3 20 3 1 4 10 2 5 - 2 2 1	13 4 4 2 2 4 - - 2 3 1 1	21 8 3 2 2 2 3 3 3 - 2 1	5 24 10 2 16 5 8 · 2 · 7 5 1 13 5 2 2 2 2	Boise, Idaho Colo. Springs, Colo Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, Utah Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawaii Long Beach, Calif. Los Angeles, Calif. Pasadena, Calif. Portland, Oreg. Sacramento, Calif.	103 188 14 126 16 80 115 1,106 11 99 4 60 74 27 19 229 192	26 39 69 133 12 78 57 86 74 45 57 19 133	5 12 19 39 15 1 13 20 205 2 16 1 9 15 5 44 41	1 6 13 2 18 1 4 7 80 3 8 - 2 1 2 1 2 1	1 2 3 8 - 4 2 17 - - - - - - - - - - - - - - - - - -	1 7 - 6 - 2 - 1 1 - 1 6 2	3 2 6 11 2 10 4 7 11 113 15 15 9 2 2 18 26
W.N. CENTRAL Des Moines, lowa Duluth, Minn. Kansas City, Kans. Kansas City, Mo. Lincoln, Nebr. Minneapolis, Minn. Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	617 119 U 15 109 17 116 54 73 65 49	439 79 U 9 75 12 87 39 49 49	32 U 3 12 4 17 12 17 9	35 3 U 2 7 10 - 6 5 1	7 U 1 3 - 1 2 -	12 5 U - 1 1 1 1 2	29 9 U - 3 - 8 5 - 4	San Diego, Calif. San Francisco, Calif San Jose, Calif. Santa Cruz, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash.	96 94 U 20 63 43 75 10,057	67 64 U 12 43 35 50 6,991	18 17 U 5 10 1 16 1,873	5 10 U 3 5 3 5 729	4 U 3 2 -	2 U 2 2 2 4 241	12 14 U 1 2 3 3 618

U: Unavailable -: no reported cases

*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

†Pneumonia and influenza.

Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

Total includes unknown ages.

Abortion Surveillance — Continued

vide, information about characteristics (e.g., age or race) of women obtaining legal abortions (two states). To track efforts to prevent unintended pregnancy, each state needs an accurate assessment of abortion on an ongoing basis (including the number and characteristics of women obtaining legal abortions). Since 1992, most reporting areas have reported abortions by gestational age in weeks of gestation for abortions performed at ≤ 8 weeks. As new medical methods are introduced and used for terminating pregnancies primarily at ≤ 8 weeks' gestation, these data will continue to assist in monitoring trends in legal abortions (8-10).

Additional statistical and epidemiologic information about legal induced abortions is available from CDC's automated Reproductive Health Information line, telephone (888) 232-2306, which provides information by fax, by voice recordings, or through the mail; or from CDC's World-Wide Web site, http://www.cdc.gov.

References

- 1. Koonin LM, Smith JC, Ramick M, Strauss LT. Abortion surveillance: United States, 1995. MMWR 1998;47(no. SS-2):31–68.
- Ventura SJ, Martin JA, Curtin SC, Mathews TJ. Report of final natality statistics, 1996. Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service, CDC, 1998; DHHS publication no.(PHS)98-1120. (Monthly vital statistics report; vol 46, no. 11, suppl 2).
- 3. CDC. Abortion surveillance—1975. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, CDC, 1977.
- 4. CDC. Abortion surveillance—1976. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, CDC, 1978.
- Abma J, Chandra A, Mosher W, Peterson L, Piccinino L. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 1997;23:1– 114
- 6. Henshaw SK. The accessibility of abortion services in the United States. Fam Plann Perspect 1991;23:246–52,263.
- 7. Henshaw SK, VanVort J. Abortion services in the United States, 1991 and 1992. Fam Plann Perspect 1994;26:100–6,112.
- 8. Peyron R, Aubeny E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993;328:1509–13.
- 9. Creinin MD, Vittinghoff E, Galbraith S, Klaisle C. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. Am J Obstet Gynecol 1995:173:1578–84.
- 10. Population Council. U.S. mifepristone clinical trials: summary of findings. New York, New York: Population Council, 1997.

Contributors to the Production of the MMWR (Weekly) Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Gerald Jones Carol A. Worsham CDC Operations Team
Carol M. Knowles
Deborah A. Adams
Willie J. Anderson
Patsy A. Hall
Amy K. Henion
Myra A. Montalbano

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov The body content should read SUBscribe mmwr-toc Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control Director, Epidemiology Program Office and Prevention Jeffrey P. Koplan, M.D., M.P.H. Deputy Director, Centers for Disease Control and Prevention Claire V. Broome, M.D.

Stephen B. Thacker, M.D., M.Sc. Editor, MMWR Series John W. Ward, M.D. Managing Editor, MMWR (weekly) Karen L. Foster, M.A.

Writers-Editors. MMWR (weekly) David C. Johnson Teresa F. Rutledge Caran R. Wilbanks Desktop Publishing and Graphics Support Morie M. Higgins Peter M. Jenkins

☆U.S. Government Printing Office: 1998-733-228/87047 Region IV